MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Sarepta Therapeutics Inc

Open

SectorGezondheidszorg

60.94 0.59

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

59.75

Max

61.86

Belangrijke statistieken

By Trading Economics

Inkomsten

125M

159M

Verkoop

191M

658M

K/W

Sectorgemiddelde

23.603

57.333

EPS

1.9

Winstmarge

24.156

Werknemers

1,372

EBITDA

138M

187M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+140.04% upside

Dividenden

By Dow Jones

Volgende Winsten

6 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-5.3B

5.4B

Vorige openingsprijs

60.35

Vorige sluitingsprijs

60.94

Technische score

By Trading Central

Vertrouwen

Very Strong Bullish Evidence

Sarepta Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

31 mrt 2025, 14:19 UTC

Belangrijke Marktbewegers

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

20 jun 2024, 23:05 UTC

Belangrijke Marktbewegers

Sarepta Shares Soar 37% Following Expanded Approval for Elevidys

21 jun 2024, 08:58 UTC

Top Nieuws

These Stocks Are Moving the Most Today: Microsoft, Nvidia, Trump Media, Sarepta, CarMax, and More -- Barrons.com

Peer Vergelijking

Prijswijziging

Sarepta Therapeutics Inc Prognose

Koersdoel

By TipRanks

140.04% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 148.25 USD  140.04%

Hoogste 209 USD

Laagste 70 USD

Gebaseerd op 22 Wall Street-analisten die 12-maands prijsdoelen bieden voor Sarepta Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

22 ratings

18

Buy

4

Hold

0

Sell

Technische score

By Trading Central

59.31 / 62.78Steun & Weerstand

Korte Termijn

Very Strong Bullish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.